| Aberrantly activated Cox-2 and Wnt signaling interact to maintain cancer stem cells in glioblastoma M Wu, J Guan, C Li, S Gunter, L Nusrat, S Ng, K Dhand, C Morshead, ... Oncotarget 8 (47), 82217, 2017 | 46 | 2017 |
| How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis NG Cunniffe, SJ Gunter, M Brown, SW Burge, C Coyle, A De Soyza, ... BMJ open 10 (10), e044566, 2020 | 13 | 2020 |
| Analysis of supportive evidence for US Food and Drug Administration approvals of novel drugs in 2020 M Mitra-Majumdar, SJ Gunter, AS Kesselheim, BL Brown, KW Joyce, ... JAMA Network Open 5 (5), e2212454-e2212454, 2022 | 12 | 2022 |
| Medicaid spending on drugs marketed without US Food and Drug Administration approval in 2020 SJ Gunter, AS Kesselheim, BN Rome JAMA Internal Medicine 182 (3), 342-345, 2022 | 5 | 2022 |
| Market exclusivity and changes in competition and prices associated with the US Food and Drug Administration Unapproved Drug Initiative SJ Gunter, AS Kesselheim, BN Rome JAMA Internal Medicine 181 (8), 1124-1126, 2021 | 5 | 2021 |
| Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab SJ Gunter, ZE Holcomb, BD Lam, ML Porter, AB Kimball JAMA dermatology, 2024 | | 2024 |
| Changes to Registered and Pivotal Clinical Trials after the 2011 Tri-Societies Guidelines for Clinical Endpoints and Response Criteria in Mycosis Fungoides and Sézary Syndrome SJ Gunter, EJ Kim Journal of Investigative Dermatology 144 (4), 855-861. e1, 2024 | | 2024 |
| Market dynamics of authorized generics in Medicaid from 2014 to 2020 BN Rome, SJ Gunter, AS Kesselheim Health Services Research 58 (4), 953-959, 2023 | | 2023 |
| 423 Baseline C-reactive protein correlates with adalimumab and placebo 3non-response in patients with hidradenitis suppurativa S Gunter, M Porter, R Gibson, AB Kimball Journal of Investigative Dermatology 143 (5), S73, 2023 | | 2023 |
